Board of Directors

Fotolia_107419345_Sm

Members of BIRAD's Board of Directors have many years of experience in corporate governance, financial markets, and prudent company management.

DR. EHUD SHAPIRA
PROF. SHULAMIT MICHAELI
DR. LIPA MEIR
DR. DAVID AVIEZER
SANFORD T. COLB
MENACHEM GREENBLUM
TAL FUHRER
DR. EHUD SHAPIRA

Dr. Ehud Shapira
Chairman of BIRAD’s Board of Directors

Dr. Ehud Shapira is also chairman of the Board of Directors of Psagot Investment House Ltd, Israel's largest investment house, as well as its subsidiaries: Psagot Securities Ltd. and Psagot Mutual Funds Ltd. Dr. Shapira has served as Chairman of the Board of Phoenix Holding Ltd. He has been on the Board of Directors of Bank Leumi, as well as holding a number of senior management positions for the Bank Leumi Group, including Senior Deputy CEO, Acting CEO, Head of Corporate and International Banking and the Risk Manager. In this last capacity, Dr. Shapira directed the Bank Leumi Group's Corporate Banking division, the Real-Estate & Construction Division, the International Division and the Credit Risks Division. Dr. Shapira is a member of the Board of Trustees and Finance Committee of the Tel Aviv Museum of Art and also serves on the Executive and Finance Committees of Bar Ilan University. Dr. Shapira holds a Ph.D. from New York University, an MSc from the Technion, and a BA from Tel Aviv University.

PROF. SHULAMIT MICHAELI

Prof. SHULAMIT MICHAELI
Vice President for Research

Appointed Vice President for Research in October 2017, Prof. Shulamit Michaeli previously served as Dean of the Mina and Everard Goodman Faculty of Life Sciences and the founding Director of the Nano-Medicine Center at the Bar-Ilan Institute for Nanotechnology and Advanced Materials (BINA). In addition, for eight years Professor Michaeli directed the Life Sciences and Medicine division of the Israel Science Foundation. Professor Michaeli has been a member of many national committees, including the prize committees for the Israel Prize and the EMET Prize. She has and participated and led European scientific associations, Israeli I-core excellence research centers, and other Israeli research groups.

A microbiologist by training and the Myers Chair in Gene Expression and Infectious Disease, Prof. Michaeli studies Trypanosomatids, the vicious order of parasites which infect millions worldwide, causing African sleeping sickness, South American Chagas disease, and leishmaniasis, or sand-fly fever, which affects a band of countries from Portugal through India, including Israel. Prof. Michaeli has pioneered the use of nanotechnology in fighting diseases creating nano-drugs for parasitic infections and cancer.

Prof. Michaeli has published more than a hundred articles in professional journals and books and patented a number of important technologies. She was the first researcher in the country to be funded by the Howard Hughes Medical Institute for ten years. She has won numerous prestigious awards, including the Israeli Society of Microbiology Award, both as a young researcher and as a senior research, and the Landau Prize, both in Medicine and more recently in Microbiology. When she was on the staff of the Weizmann Institute, she was awarded the Clore Prize for Outstanding Young Researcher and the prestigious Andre Lwoff Prize in Parasitology given by the French Academy of Sciences. And twice she has been chosen as one of the 40 leading women in Israel by Globes newspaper.

DR. LIPA MEIR

Dr. Lipa Meir
Founding Partner of Lipa Meir & Co., Law Firm

The firm was founded by Lipa in 1987 and today it is one of the largest and most prestigious law firms in Israel, with more than 80 lawyers. Following his admission to the Israel Bar Association in 1974, Dr. Lipa Meir began working as an associate at the law firm of Herzog, Fox & Neeman and in 1978 became a partner in the firm and continued to work there until 1987. Dr Meir received his Ph.D. from the University of Toronto, Canada in 1984. His doctoral thesis is in the area of Law and Economics, and focuses on the involvement of commercial banks in securities activities, and includes comparative study in this matter in regards to United States, Canada, Israel, Britain and Germany. In addition to his practice of law, Dr Meir is a member in the Board of Trustees of Bar-Ilan University and the

Chairman of the Council of Trustees and the Permanent Committee of the University. Dr Meir is also a member of the Board of Trustees of Netanya Academic College and the Chairman of the Steering Committee of the law school program for outstanding students at the College. and serves as a judge in the supreme court of the World Zionist Organization

 

DR. DAVID AVIEZER

Dr. David Aviezer
Chief Executive Officer and Director of Protalix Ltd

Dr. David Aviezer has served as Chief Executive Officer and Director of Protalix Ltd. – a publicly traded biopharmaceutical company that, among other products, markets an FDA-approved medication for Gaucher's Disease – 2002-2014. Holder of a Ph.D. in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from Bar-Ilan University, Dr. Aviezer has over 15 years’ experience in biotechnology management, advancing products from early-stage research up to their regulatory approval and commercialization. From 1997 to 2002, he served as general manager of ProChon Biotech Ltd., an Israeli company focused on orthopedic disorders. A recipient both of the Clore Foundation Award and the J.F. Kennedy Scientific Award, Dr. Aviezer was a visiting scientist at the Medical Research Division of Cyanamid – now a division of Pfizer Pharmaceuticals. Actively involved in the creation of science-related public policy, Dr. Aviezer has served on national committees both in the Ministry of Science and in the MAGNET program of Israel's Chief Scientist's Office.

SANFORD T. COLB

Sanford T. Colb
Founder of Sanford T. Colb & Co.

He is licensed to practice before the Israel Patent Office and the US Patent and Trademark Office and is a licensed attorney in Israel and in the US. Mr. Colb is a member of the American Patent Law Association, International Law Committee, Israel Association of Patent Attorneys, AIPPI, Licensing Executives Society, American Arbitration Association, International Trademark Association, Pharmaceutical Trade Marks Group, and American Bar Association. He has been a lecturer in Intellectual Property Law at Bar-Ilan University and Netanya Academic College. Mr. Colb has an MA (honors) from Cambridge University and a BA (magna cum laude) and MSc in Physics from the University of Pennsylvania. He was awarded the Silver Medal of the Royal Society of Arts, London, and was a Thouron Scholar at Cambridge University. Sanford T. Colb holds a JD degree from Harvard Law School.

MENACHEM GREENBLUM

Menachem Greenblum
Bar-Ilan University's Director General

Mr. Greenblum is a Certified Public Accountant who has served in management positions at commercial companies affiliated with the Tambour Group and as a director of public companies. In 1997 he was appointed director general of GES (Tambour Ecology) and Chairman of the Executive Council of its subsidiaries. In 2009, Mr. Greenblum was appointed Director General of the Ministry and served in this post until 2013.

TAL FUHRER

Tal Fuhrer
Vice President of Business and Corporate Development at the Neopharm Group since 2008

Founded in 1941 with 700 employees and turnover of approx 400 Million $US. Neopharm's roots are vested in the sale and marketing of novel biopharmaceuticals and healthcare products in Israel, where it is positioned as the partner-of-choice and one-stop-shop for multinational biopharmaceutical and medical corporations seeking to enter or expand their business in the Israeli biopharma and healthcare markets. Tal has been involved in the transformation of Neopharm into a rapidly-growing commercial-stage global specially-care biotech company that brings hope to patients suffering from rare, life-threatening diseases with unmet medical needs with revenues generated in over 50 countries, diversified pipeline of late and early stage novel therapies and offices in multiple continents via numerous licensing, business development and M&A transactions, including the acquisition of Fresenius Biotech (now called: Neovii) and the establishment of Orphan Technologies. Prior to Neopharm, Tal worked at Wyeth in New Jersey where he gained experience in business development and marketing. Tal is a graduate of MBA and M.Sc studies in Biotechnology at Tel Aviv University and of the Israeli Military Computing and Information Systems Institute.